You just read:

SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Libtayo® (cemiplimab-rwlc)

News provided by

SillaJen, Inc.

Jun 06, 2019, 09:00 ET